Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 3:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pneumococcal Infections Clear all
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-experienced Adults (V116-006, STRIDE-6)

NCT05420961
View directory record Official record
Conditions
Pneumonia, Pneumococcal
Interventions
V116, PCV15, PPSV23
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
50 Years and older
Enrollment
717 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
15
States / cities
Birmingham, Alabama • Glendale, Arizona • Tempe, Arizona + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2024 · Synced Sep 23, 2026, 3:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure

NCT05799976
View directory record Official record
Conditions
Pneumonia, Pneumococcal, Diabetes Mellitus, Breast Cancer, Colorectal Cancer
Interventions
Text message nudge
Behavioral
Lead sponsor
Mitesh Patel
Industry
Eligibility
18 Years and older
Enrollment
29,334 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Sep 23, 2026, 3:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Trial to Evaluate the Safety and Immunogenicity of Multivalent Pneumococcal Vaccines in Japanese Adults 18 to 49 Years of Age

NCT03642847
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
Prevnar 13, multivalent pneumococcal conjugate formulation 1, multivalent pneumococcal conjugate formulation 2
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 49 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
4
States / cities
Garden Grove, California • Long Beach, California • Honolulu, Hawaii + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2019 · Synced Sep 23, 2026, 3:26 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of the Effect of Pneumococcal Conjugate Vaccine (PCV) on Immunogenicity of Pentacel™

NCT00772928
View directory record Official record
Conditions
Diphtheria, Tetanus, Haemophilus Infection, Pertussis, Polio
Interventions
Pentacel™: HCPDT-IPV//PRP-T Vaccine and Prevnar®
Biological
Lead sponsor
Sanofi
Industry
Eligibility
42 Days to 89 Days
Enrollment
1,167 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
23
States / cities
Montgomery, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2012 · Synced Sep 23, 2026, 3:26 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Allogeneic Hematopoietic Stem Cell Transplant Recipients (V114-022/PNEU-STEM)

NCT03565900
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
V114, Prevnar 13™, PNEUMOVAX™23
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
3 Years and older
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
13
States / cities
Palo Alto, California • Aurora, Colorado • Gainesville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Sep 23, 2026, 3:26 AM EDT
Completed No phase listed Observational Results available

A Study To Learn About The Effects Of Pneumococcal Vaccine In People With HIV

NCT05794191
View directory record Official record
Conditions
HIV, Pneumonia, Infections, Pneumococcal
Interventions
Vaccine Administration
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
350,399 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 19, 2025 · Synced Sep 23, 2026, 3:26 AM EDT
Not yet recruiting Phase 3 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability, and Immunogenicity of 3 Lots of a Multivalent Pneumococcal Conjugate Vaccine Administered to Adults

NCT07794748
View directory record Official record
Conditions
Pneumococcal Disease
Interventions
PG4 Multivalent Vaccine, 20 Valent Pneumococcal Conjugate Vaccine (20vPnC)
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 49 Years
Enrollment
4,670 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
25
States / cities
Lake Forest, California • Walnut Creek, California • Milford, Connecticut + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 23, 2026, 3:26 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine

NCT00521586
View directory record Official record
Conditions
Influenza
Interventions
13 valent pneumococcal conjugate vaccine
Biological
Lead sponsor
Pfizer
Industry
Eligibility
50 Years to 59 Years
Enrollment
1,116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
41
States / cities
Chandler, Arizona • Rolling Hills Estates, California • Aurora, Colorado + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2015 · Synced Sep 23, 2026, 3:26 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)

NCT00546572
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
13 valent Pneumococcal Conjugate Vaccine, 23vPS
Biological
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
70 Years and older
Enrollment
938 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
51
States / cities
Mobile, Alabama • Mesa, Arizona • Fountain Valley, California + 43 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2011 · Synced Sep 23, 2026, 3:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Modulation of Steroid Immunosuppression by Alveolar Efferocytosis

NCT03034642
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Pneumonia, Bacterial
Interventions
Bronchoscopy with bilateral bronchoalveolar lavages
Procedure
Lead sponsor
VA Ann Arbor Healthcare System
Federal
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 2, 2022 · Synced Sep 23, 2026, 3:26 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Aerosolized and Intravenous Colistin in Healthy Adults

NCT01863719
View directory record Official record
Conditions
Pathogen Resistance, Pneumococcal Infection, Pneumonia
Interventions
Colistimethate sodium
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
2
States / cities
Baltimore, Maryland • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 1, 2020 · Synced Sep 23, 2026, 3:26 AM EDT
Active, not recruiting No phase listed Observational

A Study to Learn How Effective is PCV20 to Help Stop Adults Who Have a Higher Chance of Getting Pneumonia

NCT07251465
View directory record Official record
Conditions
Community-Acquired Pneumonia (CAP)
Interventions
Receipt of PCV20
Biological
Lead sponsor
Pfizer
Industry
Eligibility
19 Years and older
Enrollment
846,279 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 23, 2026, 3:26 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of Age

NCT00861744
View directory record Official record
Conditions
Rubella, Mumps, Measles, Measles-Mumps-Rubella Vaccine
Interventions
GSK Biological's investigational vaccine 209762, M-M-R® II (Merck and Co), Varivax®, Havrix®, Prevnar®
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Months to 15 Months
Enrollment
1,259 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
45
States / cities
Tuscaloosa, Alabama • Conway, Arkansas • Jonesboro, Arkansas + 42 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2020 · Synced Sep 23, 2026, 3:26 AM EDT
Completed Phase 3 Interventional Results available

Comparative Study of Ceftaroline vs. Ceftriaxone in Adults With Community-Acquired Pneumonia

NCT00509106
View directory record Official record
Conditions
Bacterial Pneumonia
Interventions
Ceftaroline fosamil for Injection, Ceftriaxone, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
622 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Sep 23, 2026, 3:26 AM EDT
Completed Not applicable Interventional Results available

System Alignment for VaccinE Delivery (SAVED): Improving Rates of Influenza and Pneumococcal Vaccination Through Patient Outreach, Improved Medical Record Accuracy and Targeted Physician Alerts

NCT02266277
View directory record Official record
Conditions
Influenza, Infections, Pneumococcal
Interventions
Arm 1: E-portal message with IVR call, Arm 2: E-portal message with no IVR call, Arm 3: No e-portal message with IVR call, Arm 5: IVR call
Other
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older
Enrollment
30,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Sep 23, 2026, 3:26 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants

NCT03621670
View directory record Official record
Conditions
Infections, Meningococcal
Interventions
Bexsero (GSK Biologicals' Meningococcal group-B vaccine/ rMenB+OMV NZ), Prevnar13, Pediarix, Hiberix, Rotarix, M-M-R II, Varivax, Placebo (saline water), Prevnar 20
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 12 Weeks
Enrollment
1,196 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
56
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 47 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 23, 2026, 3:26 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine in Healthy Infants

NCT03512288
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
Multivalent, 13vPnC
Biological
Lead sponsor
Pfizer
Industry
Eligibility
42 Days to 98 Days
Enrollment
460 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
39
States / cities
Fayetteville, Arkansas • Downey, California • Huntington Beach, California + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2021 · Synced Sep 23, 2026, 3:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Pharmacist Impact on Pneumococcal Polysaccharide Vaccination Rates in Patients With Diabetes in a Supermarket Pharmacy Chain

NCT03851978
View directory record Official record
Conditions
Pneumococcal Pneumonia
Interventions
Pharmacist Vaccine Education
Behavioral
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
19 Years to 64 Years
Enrollment
431 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
4
States / cities
Midlothian, Virginia • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 14, 2019 · Synced Sep 23, 2026, 3:26 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Infants

NCT05844423
View directory record Official record
Conditions
Pneumococcal Vaccines
Interventions
0.5 ml dose of 1.1 mcg VAX-24, 0.5 ml dose of PCV20, 0.5 ml dose of 2.2 mcg VAX-24, 0.5 ml dose of 2.2/4.4 mcg VAX-24
Biological
Lead sponsor
Vaxcyte, Inc.
Industry
Eligibility
42 Days to 89 Days
Enrollment
802 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
32
States / cities
Jonesboro, Arkansas • Madera, California • Tampa, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Sep 23, 2026, 3:26 AM EDT
Completed Not applicable Interventional

Study of Anti-HIV Therapy Intensification

NCT00034086
View directory record Official record
Conditions
HIV Infections
Interventions
Lopinavir/Ritonavir, Lamivudine/Zidovudine, Tenofovir disoproxil fumarate, Pneumococcal Vaccine, Polyvalent (23-valent), Lamivudine, Stavudine, Zidovudine, Didanosine, Lyme Disease Vaccine Recombinant OspA, Haemophilus B Conjugate Vaccine
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2006
U.S. locations
3
States / cities
Aurora, Colorado • Chicago, Illinois • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 17, 2012 · Synced Sep 23, 2026, 3:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Improving Pneumococcal Vaccination Rates in an Ambulatory Pre-surgical Testing Setting

NCT01787838
View directory record Official record
Conditions
Community Acquired Pneumonia
Interventions
Focused Health Education
Other
Lead sponsor
Carilion Clinic
Other
Eligibility
18 Years to 110 Years
Enrollment
2,509 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 18, 2017 · Synced Sep 23, 2026, 3:26 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Tolerability, Safety and Immunogenicity of MVX01 Pneumococcal Vaccine

NCT06337643
View directory record Official record
Conditions
Pneumococcal Vaccine
Interventions
MVX01, MVX01 Placebo
Biological
Lead sponsor
Matrivax Research and Development Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
Savannah, Georgia • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 28, 2024 · Synced Sep 23, 2026, 3:26 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Vaccine in Adults 65 Years of Age or Older With Prior Pneumococcal Vaccination

NCT03835975
View directory record Official record
Conditions
Pneumococcal Disease
Interventions
13vPnC, PPSV23, 20vPnC
Biological
Lead sponsor
Pfizer
Industry
Eligibility
65 Years and older
Enrollment
875 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
34
States / cities
Mobile, Alabama • Chandler, Arizona • Peoria, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2021 · Synced Sep 23, 2026, 3:26 AM EDT
Completed Phase 4 Interventional Results available

Assessing the Use of Certolizumab Pegol in Adult Subjects With Rheumatoid Arthritis on the Antibody Response When Receiving Influenza Virus and Pneumococcal Vaccines

NCT00993668
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Placebo, Certolizumab pegol
Other · Biological
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
41
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Sep 23, 2026, 3:26 AM EDT